keyword
https://read.qxmd.com/read/38189111/clinical-guidance-for-choosing-the-right-pharmacotherapy-for-migraine-attacks
#21
JOURNAL ARTICLE
Izabela Domitrz
INTRODUCTION: Migraine as headache attacks with autonomic symptoms is a serious condition and it is important to treat a single attack effectively in order to improve not only the patient's quality of life at a given moment but also to prevent the migraine from becoming a chronic one. AREA COVERED: The article briefly presents the guidance in selecting the most appropriate pharmacological treatment of migraine attack, indicating a personalized approach to migraine patient...
January 8, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38157876/the-history-and-rationale-of-the-development-of-new-drugs-for-migraine-treatment
#22
JOURNAL ARTICLE
Pedro André Kowacs, Pedro Augusto Sampaio Rocha-Filho, Mário Fernando Prieto Peres, Lars Edvinsson
Migraine is one of the most prevalent and disabling diseases in the world. Migraine attack treatments and prophylactic treatments of this disease are essential to lessen its individual, social, and economic impact. This is a narrative review of the main drugs used for treating migraine, as well as the experimental models and the theoretical frameworks that led to their development. Ergot derivatives, triptans, non-steroid anti-inflammatory drugs, tricyclic antidepressants, beta-blockers,: flunarizine,: valproic acid,: topiramate, onabotulinumtoxin A, ditans, monoclonal antibodies against CGRP and its receptor, and gepants are discussed...
December 2023: Arquivos de Neuro-psiquiatria
https://read.qxmd.com/read/38116186/editorial-novel-migraine-therapies-consolidating-evidence-from-the-real-world
#23
EDITORIAL
Lanfranco Pellesi
No abstract text is available yet for this article.
2023: Front Pain Res (Lausanne)
https://read.qxmd.com/read/38053061/what-to-do-with-non-responders-to-cgrp-r-monoclonal-antibodies-switch-to-another-or-move-to-gepants
#24
EDITORIAL
Marta Waliszewska-Prosół, Doga Vuralli, Paolo Martelletti
In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential benefits of changing CGRP-targeted treatment.
December 5, 2023: Journal of Headache and Pain
https://read.qxmd.com/read/38030397/simultaneous-comparisons-of-25-acute-migraine-medications-based-on-10-million-users-self-reported-records-from-a-smartphone-application
#25
JOURNAL ARTICLE
Chia-Chun Chiang, Xuemin Fang, Zsolt Horvath, Francois Cadiou, Alexandre Urani, Weijie Poh, Hiroto Narimatsu, Yu Cheng, David W Dodick
BACKGROUND AND OBJECTIVES: Many acute treatment options exist for migraine. However, large-scale, head-to-head comparisons of treatment effectiveness from real-world patient experience reports are lacking. METHODS: This is a retrospective analysis of 10,842,795 migraine attack records extracted from an e-diary smartphone application between June 30, 2014, and July 2, 2020. We analyzed 25 acute medications among 7 classes-acetaminophen, nonsteroid anti-inflammatory drugs (NSAIDs), triptans, combination analgesics, ergots, antiemetics, and opioids...
December 12, 2023: Neurology
https://read.qxmd.com/read/37996401/new-drugs-targeting-calcitonin-gene-related-peptide-for-the-management-of-migraines
#26
REVIEW
Claudio Tana, Francesco Cipollone, Maria Adele Giamberardino, Paolo Martelletti
INTRODUCTION: Significant advances in migraine research have contributed to the development of new drugs for the treatment of migraine. Monoclonal antibodies (mAbs) against Calcitonin Gene-Related Peptide (CGRP) or its receptor and CGRP receptor antagonists (gepants) have been associated with a good safety profile and resulted in an overall efficacy in reducing the number of monthly migraine days both in episodic and chronic forms of migraine. AREAS COVERED: The results from main investigation studies (phase 2 or 3) of CGRP-targeting drugs (both anti-CGRP mAbs and gepants) are reported in this expert-opinion review...
December 2023: Expert Opinion on Emerging Drugs
https://read.qxmd.com/read/37948006/comparing-the-efficacy-and-safety-of-galcanezumab-versus-rimegepant-for-prevention-of-episodic-migraine-results-from-a-randomized-controlled-clinical-trial
#27
JOURNAL ARTICLE
Todd J Schwedt, Tina M Myers Oakes, James M Martinez, Bert B Vargas, Hitendra Pandey, Eric M Pearlman, Diane R Richardson, Oralee J Varnado, Michael Cobas Meyer, Peter J Goadsby
INTRODUCTION: There have been no prior trials directly comparing the efficacy of different calcitonin gene-related peptide (CGRP) antagonists for migraine prevention. Reported are the results from the first head-to-head study of two CGRP antagonists, galcanezumab (monoclonal antibody) versus rimegepant (gepant), for the prevention of episodic migraine. METHODS: In this 3-month, double-blind, double-dummy study, participants were randomized (1:1) to subcutaneous (SC) galcanezumab 120 mg per month (after a 240 mg loading dose) and a placebo oral disintegrating tablet (ODT) every other day (q...
February 2024: Neurology and Therapy
https://read.qxmd.com/read/37943442/unmet-needs-in-the-acute-treatment-of-migraine
#28
JOURNAL ARTICLE
Enrico Bentivegna, Silvia Galastri, Dilara Onan, Paolo Martelletti
Migraine represents the most common neurologic disorder, ranking second among the world's causes of disability [expressed as years lived with disability (YLDs)]. Patients often do not receive the best therapy because of safety issues, tolerance, and prescription accessibility. General practitioners are not always educated about the disease, and specialists are few and often difficult to reach. Therapies are limited and have many side effects that can impede the prescription. Prophylactic therapy is recommended in case of four or more headaches a month, eight or more headache days a month, debilitating headaches, and medication-overuse headaches...
November 9, 2023: Advances in Therapy
https://read.qxmd.com/read/37942638/gepants-in-the-acute-management-of-migraine
#29
EDITORIAL
William David Wells-Gatnik, Paolo Martelletti
No abstract text is available yet for this article.
November 2023: Pain Management
https://read.qxmd.com/read/37925645/metabolic-and-toxicological-considerations-regarding-cgrp-mabs-and-cgrp-antagonists-to-treat-migraine-in-covid-19-patients-a-narrative-review
#30
REVIEW
Tsubasa Takizawa, Keiko Ihara, Shunsuke Uno, Seiya Ohtani, Narumi Watanabe, Noboru Imai, Jin Nakahara, Satoko Hori, David Garcia-Azorin, Paolo Martelletti
INTRODUCTION: Migraine pharmacological therapies targeting calcitonin gene-related peptide (CGRP), including monoclonal antibodies and gepants, have shown clinical effect and optimal tolerability. Interactions between treatments of COVID-19 and CGRP-related drugs have not been reviewed. AREAS COVERED: An overview of CGRP, a description of the characteristics of each CGRP-related drug and its response predictors, COVID-19 and its treatment, the interactions between CGRP-related drugs and COVID-19 treatment, COVID-19 and vaccination-induced headache, and the neurological consequences of Covid-19...
November 5, 2023: Expert Opinion on Drug Metabolism & Toxicology
https://read.qxmd.com/read/37817093/triptan-non-response-in-specialized-headache-care-cross-sectional-data-from-the-dmkg-headache-registry
#31
JOURNAL ARTICLE
Ruth Ruscheweyh, Gudrun Gossrau, Thomas Dresler, Tobias Freilinger, Stefanie Förderreuther, Charly Gaul, Torsten Kraya, Lars Neeb, Victoria Ruschil, Andreas Straube, Jörg Scheidt, Tim Patrick Jürgens
BACKGROUND: Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or tolerability of ≥ 2 triptans ('triptan resistance') could be considered eligible for treatment with the novel medications from the ditan and gepant groups. There is little data on the frequency of 'triptan resistance'. METHODS: We used patient self-report data from the German Migraine and Headache Society (DMKG) Headache Registry to assess triptan response and triptan efficacy and/or tolerability failure...
October 10, 2023: Journal of Headache and Pain
https://read.qxmd.com/read/37792218/consensus-based-recommendations-on-the-use-of-cgrp-based-therapies-for-migraine-prevention-in-the-uae
#32
JOURNAL ARTICLE
Taoufik Alsaadi, Deeb M Kayed, Abubaker Al-Madani, Ali Mohamed Hassan, Alessandro Terruzzi, Derk Krieger, Naji Riachi, Pournamy Sarathchandran, Suhail Al-Rukn
INTRODUCTION: Migraine is a common debilitating neurological disorder affecting a large proportion of the general population. Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, plays a key role in the pathophysiology of migraine, and the development of therapies targeting the anti-CGRP pathway has revolutionized the field of migraine treatment. METHODS: An expert task force of neurologists in the United Arab Emirates (UAE) developed and critically assessed recommendations on the use of CGRP-based therapies in migraine treatment and management in the UAE, based on available published literature...
October 4, 2023: Neurology and Therapy
https://read.qxmd.com/read/37691118/mode-and-site-of-action-of-therapies-targeting-cgrp-signaling
#33
REVIEW
Alejandro Labastida-Ramírez, Edoardo Caronna, Cédric Gollion, Emily Stanyer, Austeja Dapkute, Diana Braniste, Hoda Naghshineh, Liga Meksa, Nino Chkhitunidze, Tamari Gudadze, Patricia Pozo-Rosich, Rami Burstein, Jan Hoffmann
Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed...
September 11, 2023: Journal of Headache and Pain
https://read.qxmd.com/read/37657674/towards-precision-medicine-in-migraine-recent-therapeutic-advances-and-potential-biomarkers-to-understand-heterogeneity-and-treatment-response
#34
REVIEW
Gabriella Juhasz, Kinga Gecse, Daniel Baksa
After 35 years since the introduction of the International Classification of Headache Disorders (ICHD), we are living in the era of the second great revolution in migraine therapies. First, discoveries of triptans provided a breakthrough in acute migraine treatment utilizing bench-to-bedside research results on the role of serotonin in migraine. Next, the discovery of the role of neuropeptides, more specifically calcitonin gene-related peptide (CGRP) in migraine attack led to the development of anti-CGRP therapies that are effective both in acute and preventive treatment, and are also able to reduce migraine-related burden...
October 2023: Pharmacology & Therapeutics
https://read.qxmd.com/read/37656319/update-of-gepants-in-the-treatment-of-chronic-migraine
#35
REVIEW
Soohyun Cho, Byung-Kun Kim
PURPOSE OF REVIEW: Despite the unmet therapeutic needs of patients with chronic migraine (CM) and/or medication overuse, available treatment options are limited. Recently, four calcitonin gene-related peptide receptor antagonists, known as gepants, have been approved for the treatment of migraine. This review focuses on the preventive treatment of CM with gepants and highlights recent findings. RECENT FINDINGS: Two randomized controlled trials (RCTs) have shown promising results for rimegepant and atogepant as preventive treatments for CM...
October 2023: Current Pain and Headache Reports
https://read.qxmd.com/read/37630989/blocking-the-cgrp-receptor-differences-across-human-vascular-beds
#36
JOURNAL ARTICLE
Tessa de Vries, Deirdre M Boucherie, Antoon van den Bogaerdt, A H Jan Danser, Antoinette MaassenVanDenBrink
Multiple drugs targeting the calcitonin gene-related peptide (CGRP) receptor have been developed for the treatment of migraine. Here, the effect of the small-molecule CGRP receptor antagonist zavegepant (0.1 nM-1 µM) on CGRP-induced relaxation in isolated human coronary arteries (HCAs) was investigated. A Schild plot was constructed and a pA2 value was calculated to determine the potency of zavegepant. The potency and Schild plot slopes of atogepant, olcegepant, rimegepant, telcagepant, ubrogepant and zavegepant in HCAs and human middle meningeal arteries (HMMAs), obtained from our earlier studies, were compared...
July 28, 2023: Pharmaceuticals
https://read.qxmd.com/read/37621262/migraine-management-for-the-otolaryngologist
#37
REVIEW
Kaitlyn A Brooks, Karen Tawk, Hamid R Djalilian, Candace E Hobson
OBJECTIVE: To characterize migraine pathophysiology, presentation, and current treatment strategies, specifically in regard to vestibulocochlear manifestations of migraine. METHODS: Narrative review of available literature. RESULTS: Migraine disorder can be described as a spectrum of otologic manifestations, with vestibular migraine now recognized with fully-fledged diagnostic criteria. Otologic manifestations are theorized to be due, in part, to trigeminal innervation of the inner ear structures and calcitonin gene-related peptide (CGRP) expression within the labyrinth...
August 2023: Laryngoscope Investigative Otolaryngology
https://read.qxmd.com/read/37604658/beyond-the-guidelines-a-narrative-review-of-treatments-on-the-horizon-for-migraine-in-children-and-adolescents
#38
REVIEW
Juliana H VanderPluym, M Cristina C Victorio, Christopher B Oakley, Reena G Rastogi, Serena L Orr
Migraine is common in children and adolescents and can cause significant disability. There are relatively limited evidence-based treatment options available, especially when compared with treatment of migraine in adults. The Pediatric Research Equity Act requires the study of a new drug or biologic in pediatric populations. As such it is mandatory that the newest migraine treatment options available for adults be evaluated in children and adolescents. It will take years before results from clinical trials in pediatric patients become available...
October 31, 2023: Neurology
https://read.qxmd.com/read/37593294/safety-and-efficacy-of-zavegepant-in-treating-migraine-a-systematic-review
#39
REVIEW
Zainab Z Khan, Usman Ahmed, Faizan Shahzad, Muaz Ali, Kashif Tousif, Usman Ahmed, Qazi Muhammad Safwan, Syed Imam Naufil, Sara Murtaza, Sajeel Saeed, Jawad Basit, Tehseen Haider, Haroon Shabbir
Drugs that act on the calcitonin gene-related peptide (CGRP) pathway herald the dawn of a new era in the management of migraine headaches. The blockade of CGRP alleviates neural inflammation and has been associated with reduced pain sensitization. Zavegepant is a third-generation drug and is the first intranasal CGRP antagonist to be developed. This systematic review aims to assess the safety, efficacy, pharmacokinetics, and tolerability of Zavegepant as an abortive treatment for migraine. Studies that assessed the safety, tolerability, and efficacy of Zavegepant for migraine were identified through a systematic literature review of PubMed, Clinicaltrials...
July 2023: Curēus
https://read.qxmd.com/read/37569648/migraine-treatment-towards-new-pharmacological-targets
#40
REVIEW
Marcello Silvestro, Luigi Francesco Iannone, Ilaria Orologio, Alessandro Tessitore, Gioacchino Tedeschi, Pierangelo Geppetti, Antonio Russo
Migraine is a debilitating neurological condition affecting millions of people worldwide. Until a few years ago, preventive migraine treatments were based on molecules with pleiotropic targets, developed for other indications, and discovered by serendipity to be effective in migraine prevention, although often burdened by tolerability issues leading to low adherence. However, the progresses in unravelling the migraine pathophysiology allowed identifying novel putative targets as calcitonin gene-related peptide (CGRP)...
July 31, 2023: International Journal of Molecular Sciences
keyword
keyword
66658
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.